This study identified a relatively large magnitude of death (10%) among under-five children taking treatment for SAM compared to most previous reports in other parts of the country (21, 22, 27–29) and elsewhere in SSA (30–32) suggesting that the international target of achieving less than 10% death rate (33) is yet to be attained in the study settings. Our study identified important underlying clinical conditions affecting the success of SAM treatment.
Children admitted with hypothermia were more likely to die during the course of the treatment compared to those without the condition. In children with SAM, hypothermia often results from adaptation to the low caloric intake or reduced energy expenditure. It may also indicate coexisting hypoglycaemia or serious infection (25). Metabolic changes following hypothermia often causes poor appetite leading to loss of stored energy and severe wasting (marasmus) increasing the risk of death (10, 25, 34–36). The current finding supports the clinical significance of hypothermia for the success of SAM treatment that has previously been reported by many studies (8, 14, 17, 24, 27, 29, 33, 35). It underscores the importance of an appropriate management of the condition during admission to SAM treatment in accordance with the national and international guidelines (25, 34).
Another clinical condition significantly associated with death among children on SAM treatment is admission with shock. Sock is a commonly co-existing clinical condition in children with SAM and often accompanied by dehydration and sepsis (25). Beyond being an independent predictor of death per se in this and several other studies (1, 37–40), severe dehydration leads to shock in SAM cases particularly when exacerbated by other clinical conditions such as septicaemia (41). Many studies previously reported shock as one of the most common causes of death in children under SAM treatment (34, 42). It seems imperative to identify and manage early the potential causes of shock in addition to handling the case itself.
The presence of anaemia during admission increased the likelihood of death due to SAM. Anaemia is also one of the most common co-existing clinical conditions with SAM, which might be attributable to micronutrient (especially of iron) deficiency mainly as a result of appetite loss, bacteraemia and/or other possible infections due to depletion of immunity (1, 34). The link between anaemia and death among children under SAM treatment is well established (1, 8, 15, 27, 43–45) suggesting the importance of timely management of the causes as well as the condition in order to enhance effectiveness of the treatment.
Children with TB were more likely to die while taking SAM treatment compared to those without the infection. The risk of TB in children under SAM is high due to lower immunity attributable to SAM itself and other possible co-existing immune suppressing infections such as HIV (30, 46). TB co-existence with SAM severely compromises already weakened immunity and further complicates the condition leading to poor treatment outcome (1, 34). TB is among the known clinical conditions adversely affecting SAM treatment (11, 12, 18, 44, 47) requiring early diagnosis and treatment.
Our study is subject to several limitations. The study did not include treatment defaulters and children who were transferred out who might have different treatment outcomes than those included in the study. The use of medical records as a data source limited our capacity to consider other relevant contextual variables (especially those related to socioeconomic circumstances) in the analyses. Causality between the predictor variables and the outcome variable cannot be claimed as the study analysed the data at point in time. Although it is highly likely that the results are similar in other settings as they are of mostly clinical and physiological conditions, purposeful selection of the health care facilities may limit generalisability of some of the findings.